Incanthera plc (AQSE: INC), a UK-based company specialising in dermatology and oncology innovations, on Wednesday announced new independent research validating the protective and energising properties of its skincare brand, Skin + CELL.

The study, conducted by Skin Life Analytics Ltd in Newcastle, shows that Skin + CELL significantly reduces UV-induced mitochondrial DNA damage in human skin cells. Pre-treatment with 1% Skin + CELL for six days resulted in a 6.5-fold reduction in UV-related damage, highlighting strong potential in protecting against cellular ageing.

Data from the Seahorse Bioanalyser further confirmed a substantial increase in cellular energy production, indicating enhanced mitochondrial function alongside protection. The product also demonstrated high tolerability, showing no cytotoxicity in human skin fibroblasts.

Skin + CELL is part of Incanthera's strategy to apply clinically developed technologies to luxury skincare. Its range spans face, body, hand, serum, and eye cream formulations, with planned extensions to include SPF and vitamin derivatives.

Founded out of the Institute of Cancer Therapeutics at the University of Bradford, Incanthera aims to identify and advance clinical technologies through early-stage commercial partnerships.